Skip to main content

Table 1 Cohort description

From: Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study

Feature

HC

Relatives

SCD

MCI

DAT

p

 

n = 74

n = 23

n = 99

n = 75

n = 38

 

Age (yrs.), median (SD)

68 (5)

64 (4)

71 (6)

73 (5)

75 (7)

2 × 10E−10

Sex (male), n (%)

40 (54)

17 (74)

44 (44)

23 (31)

25 (63)

4 × 10E−4

APOE (ε4 positive), n (%)

16 (22)

8 (35)

35 (35)

29 (39)

25 (66)

3 × 10E−4

BMI, median (SD)

25 (3)

26 (4)

25 (3)

26 (4)

24 (4)

0.084

Aβ42/40, median (SD)

0.097 (0.021)

0.100 (0.024)

0.095 (0.027)

0.066 (0.030)

0.046 (0.017)

9 × 10E−15

Aβ42/40 < 0.08, n (%)

17 (23)

4 (17)

36 (36)

43 (57)

35 (92)

7 × 10E−13

t-tau (pg/ml), median (SD)

368 (159)

372 (104)

368 (192)

483 (262)

804 (342)

7 × 10E−13

t-tau > 510.9, n (%)

15 (20)

3 (13)

21 (21)

34 (45)

31 (82)

2 × 10E−12

p-tau-181 (pg/ml), median (SD)

49.4 (18.4)

43.4 (12.1)

47.3 (24.4)

63.2 (31.7)

87.5 (39.6)

5 × 10E−10

p-tau-181 > 73.65, n (%)

8 (8)

0 (0)

12 (12)

24 (32)

28 (74)

6 × 10E−17

A− T−, n (%)

55 (74.3)

19 (82.6)

60 (60.6)

30 (40.5)

3 (7.9)

3 × 10E−17

A− T+, n (%)

2 (2.7)

0 (0.0)

3 (3.0)

2 (2.7)

0 (0.0)

A+ T−, n (%)

13 (17.6)

4 (17.4)

27 (27.3)

20 (27.0)

7 (18.4)

A+ T+, n (%)

4 (5.4)

0 (0.0)

9 (9.1)

22 (29.7)

28 (73.7)

PACC5 score, median (SD)

0.57 (0.41)

0.31 (0.65)

0.38 (0.50)

−0.74 (0.64)

−1.93 (0.57)

< 1 × 10E−15

Mean follow-up time (yrs., SD)

3.5 (1.1)

3.0 (1.4)

3.5 (1.3)

2.7 (1.4)

2.0 (1.4)

2 × 10E−6

Braak I, median (SD)

0.28 (0.66)

0.43 (0.46)

0.28 (0.73)

−0.05 (1.21)

−1.14 (1.05)

6 × 10E−12

Braak II, median (SD)

0.43 (0.72)

0.41 (0.73)

0.34 (0.74)

−0.37 (0.95)

−1.52 (0.92)

< 1 × 10E−15

Braak III, median (SD)

0.32 (0.55)

0.25 (0.47)

0.28 (0.50)

−0.32 (0.67)

−0.55 (0.94)

5 × 10E−14

Braak IV, median (SD)

0.29 (0.51)

0.25 (0.44)

0.07 (0.48)

−0.28 (0.66)

−0.58 (0.80)

6 × 10E−12

Braak V, median (SD)

0.30 (0.48)

0.43 (0.40)

0.13 (0.53)

−0.24 (0.65)

−0.55 (0.79)

3 × 10E−11

Braak VI, median (SD)

0.11 (0.72)

0.25 (0.67)

0.05 (0.65)

−0.34 (0.80)

−0.04 (0.98)

0.001

  1. The table describes demographic features, AD routine biomarkers, AT classification composition, cognitive performance (PACC5) score with follow-up period, and the structural Braak ROI scores between the screening diagnosis groups of the DELCODE sub-cohort used in this study. By DELCODE screening diagnosis, the cohort included 74 cognitively healthy controls (HC), 99 subjective cognitive decline (SCD) subjects, 75 mild cognitive impairment (MCI) subjects, 38 patients with dementia of the Alzheimer’s type (DAT) subjects, and 23 cognitively normal first-degree relatives of DAT patients. Diagnosis groups with more pronounced clinical phenotype had significantly larger fractions of AT biomarker-positive subjects. Continuous features (e.g., age) were compared by the Kruskal–Wallis test and categorical variables (e.g., sex) by the chi-square test